Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. is making strides in mental health with Dr. Rachael Sumner presenting groundbreaking women’s health trials, aiming to treat PMS and PMDD more effectively with fewer side effects. The company is advancing with multiple Phase 2B trials using MB22001, a self-administered microdosing form of LSD, and is set to release promising secondary data from a Phase 2A depression trial that has already shown significant symptom reduction.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
